<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00527605</url>
  </required_header>
  <id_info>
    <org_study_id>ARI108898</org_study_id>
    <nct_id>NCT00527605</nct_id>
  </id_info>
  <brief_title>Dutasteride 0.5mg For The Treatment Of Chinese Patients With Benign Prostatic Hyperplasia (BPH)</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Six-month Parallel-group Study to Assess Efficacy and Safety of Dutasteride 0.5mg Once Daily in Chinese Patients With Benign Prostatic Hyperplasia (BPH), Followed by a 12-month Open-label Treatment Phase</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, double-blind, placebo-controlled, six-month parallel-group study assess
      efficacy and safety of dutasteride 0.5mg once daily in Chinese patients with Benign Prostatic
      Hyperplasia (BPH) , followed by a 12-month open-label treatment phase
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline in the Prostate Volume at Month 6</measure>
    <time_frame>Baseline and Month 6</time_frame>
    <description>Percent change from baseline was calculated as the prostate volume at Month 6 minus the volume at baseline, divided by the prostate volume at baseline and multiplied by 100. Prostate volume was measured by transrectal ultrasound.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in the Prostate Volume at Month 3</measure>
    <time_frame>Baseline and Month 3</time_frame>
    <description>Percent change from baseline was calculated as the prostate volume at Month 3 minus the volume at baseline, divided by the prostate volume at baseline and multiplied by 100. Prostate volume was measured by transrectal ultrasound.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Prostate Volume at Month 6</measure>
    <time_frame>Baseline and Month 6</time_frame>
    <description>Change from baseline was calculated as the prostate volume at Month 6 minus the volume at baseline. Prostate volume was measured by transrectal ultrasound.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Prostate Volume at Month 3</measure>
    <time_frame>Baseline and Month 3</time_frame>
    <description>Change from baseline was calculated as the prostate volume at Month 3 minus the volume at baseline. Prostate volume is measured by transrectal ultrasound.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in the Serum Dihydrotestosterone (DHT) at Month 6</measure>
    <time_frame>Baseline and Month 6</time_frame>
    <description>Percent change from baseline was calculated as serum DHT at month 6 minus the value at baseline ,divided by the baseline value and multiplied by 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in the Serum DHT at Month 3</measure>
    <time_frame>Baseline and Month 3</time_frame>
    <description>Percent change from baseline was calculated as the DHT at Month 3 minus the value at baseline, divided by the baseline value and multiplied by 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Serum DHT at Month 6</measure>
    <time_frame>Baseline and Month 6</time_frame>
    <description>Change from baseline was calculated as the value of DHT at Month 6 minus the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Serum DHT at Month 3</measure>
    <time_frame>Baseline and Month 3</time_frame>
    <description>Change from baseline was calculated as the value of DHT at Month 3 minus the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in the American Urological Association Symptom Index (AUA-SI) Score at Month 6</measure>
    <time_frame>Baseline and Month 6</time_frame>
    <description>Percent change from baseline is calculated as the AUA-SI score at month 6 minus the baseline AUA-SI score, divided by the baseline score and multiplied by 100. AUA-SI is a self-administered questionnaire that assesses the severity of benign prostatic hyperplasia symptoms. Scores range from 0 to 35; mild, 0-7; moderate, 8-19; severe, 20-35.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in the AUA-SI Score at Month 3</measure>
    <time_frame>Baseline and Month 3</time_frame>
    <description>Percent change from baseline is calculated as the AUA-SI score at month 3 minus the baseline AUA-SI score, divided by the baseline score and multiplied by 100. AUA-SI is a self-administered questionnaire that assesses the severity of benign prostatic hyperplasia symptoms. Scores range from 0 to 35; mild, 0-7; moderate, 8-19; severe, 20-35.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the AUA-SI Score at Month 6</measure>
    <time_frame>Baseline and Month 6</time_frame>
    <description>Change from baseline was calculated as the AUS-SI score at month 6 minus the baseline score. AUA-SI is a self-administered questionnaire that assesses the severity of benign prostatic hyperplasia symptoms. Scores range from 0 to 35; mild, 0-7; moderate, 8-19; severe, 20-35.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the AUA-SI Score at Month 3</measure>
    <time_frame>Baseline and Month 3</time_frame>
    <description>Change from baseline was calculated as the AUA-SI score at month 3 minus the baseline score. AUA-SI is a self-administered questionnaire that assesses the severity of benign prostate hyperplasia symptoms. Scores range from 0 to 35; mild, 0-7; moderate, 8-19; severe, 20-35.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Maximum Urinary Flow Rate (Qmax) at Month 6</measure>
    <time_frame>Baseline and Month 6</time_frame>
    <description>Percent change from baseline was calculated as Qmax at Month 6 minus Qmax at baseline, divided by baseline Qmax and multiplied by 100. Qmax is the peak urinary flow measured by a uroflow meter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Qmax at Month 3</measure>
    <time_frame>Baseline and Month 3</time_frame>
    <description>Percent change from baseline was calculated as Qmax at Month 3 minus Qmax at baseline, divided by baseline Qmax and multiplied by 100. Qmax is the peak urinary flow measured by a uroflow meter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Qmax at Month 6</measure>
    <time_frame>Baseline and Month 6</time_frame>
    <description>Change from baseline was calculated as Qmax at Month 6 minus Qmax at baseline. Qmax is the peak urinary flow measured by a uroflow meter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Qmax at Month 3</measure>
    <time_frame>Baseline and Month 3</time_frame>
    <description>Change from baseline was calculated as Qmax at Month 3 minus Qmax at baseline. Qmax is the peak urinary flow measured by a uroflow meter.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">253</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <condition>Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dutasteride 0.5mg once daily orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo matched once daily orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dutasteride 0.5mg capsule</intervention_name>
    <description>Dutasteride 0.5mg once daily orally</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dutasteride matched placebo</intervention_name>
    <description>Dutasteride matched placebo once daily orally</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:

          -  Clinical diagnosis of BPH

          -  AUA-SI &gt;=12 [American Urological Association Symptom Index]

          -  Qmax &gt; 5ml/sec and &lt;=15ml/sec and minimum voided volume of &gt;=125ml

          -  Prostate volume &gt;=30cm(3)

        Exclusion:

          -  Post void residual volume &gt;250ml

          -  History or evidence of prostate cancer

          -  Total serum PSA &lt;1.5ng/ml or &gt;10.0ng/ml (Prostate specific antigen)

          -  Previous prostatic surgery or other invasive procedures to treat BPH.

          -  History of AUR (Acute Urinary Retention) within 3 months

          -  History of flexible/rigid cystoscopy or other instrumentation of the urethra within 7
             days

          -  Any causes other than BPH, which may in the judgement of the investigator, result in
             urinary symptoms or changes in flow rate

          -  History of hepatic impairment or abnormal liver function tests

          -  Use of any 5a-reductase inhibitors ,any drugs with antiandrogenic properties or other
             drugs noted for gynaecomastia effects, or could affect prostate volume, within past 6
             months and throughout the study

          -  Use of alpha-receptor blockers within 2 weeks and throughout the study.

          -  Use of phytotherapy for BPH within 2 weeks and/or predicted to need phytotherapy
             during the study.

          -  Concurrent use of anabolic steroids

          -  Use of any alpha-adrenergic agonists or cholinergics within 48 hours prior to
             uroflowmetry assessment.

          -  Hypersensitivity to any 5a-reductase inhibitor or other chemically-related drugs.

          -  Actively trying to procreate or unwilling to wear a condom during intercourse with a
             woman of childbearing potential for duration of participation in this study and 16
             weeks following treatment.

          -  History or current evidence of drug or alcohol abuse within the previous 12 months.

          -  History of any illness that in the opinion of the investigator might confound the
             results of the study or poses additional risk to the patient.

          -  Any unstable, serious co-existing medical condition(s) including, but not limited to,
             myocardial infarction, coronary bypass surgery, unstable angina, cardiac arrhythmias,
             clinically evident congestive heart failure, of cerebrovascular accident within 6
             months prior to Screening visit; uncontrolled diabetes or peptic ulcer disease which
             is uncontrolled by medical management.

          -  History of renal insufficiency, or serum creatinine &gt;1.5xULN (Upper Limit of Normal )

          -  Participation in any investigational or marketed drug trial within 30 days and during
             the course of the study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510180</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Beijing</city>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Beijing</city>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Beijing</city>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tianjin</city>
        <zip>300211</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <removed_countries>
    <country>Argentina</country>
  </removed_countries>
  <reference>
    <citation>Na Y, Ye Z, Zhang S; Chinese Dutasteride Phase III Trial (ARIA108898) Study Group. Efficacy and safety of dutasteride in Chinese adults with symptomatic benign prostatic hyperplasia: a randomized, double-blind, parallel-group, placebo-controlled study with an open-label extension. Clin Drug Investig. 2012 Jan 1;32(1):29-39. doi: 10.2165/11593750-000000000-00000.</citation>
    <PMID>22017520</PMID>
  </reference>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2007</study_first_submitted>
  <study_first_submitted_qc>September 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2007</study_first_posted>
  <results_first_submitted>February 22, 2010</results_first_submitted>
  <results_first_submitted_qc>February 22, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 11, 2010</results_first_posted>
  <last_update_submitted>March 15, 2012</last_update_submitted>
  <last_update_submitted_qc>March 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 21, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>placebo control</keyword>
  <keyword>Chinese</keyword>
  <keyword>Dutasteride</keyword>
  <keyword>Randomized</keyword>
  <keyword>Benign Prostatic Hyperplasia</keyword>
  <keyword>Double blind</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dutasteride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dutasteride 0.5 mg</title>
          <description>Oral dutasteride 0.5 milligrams (mg) once a day for 6 months</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Matching oral placebo once a day for 6 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="126"/>
                <participants group_id="P2" count="127"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="113"/>
                <participants group_id="P2" count="116"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dutasteride 0.5 mg</title>
          <description>Oral dutasteride 0.5 milligrams (mg) once a day for 6 months</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Matching oral placebo once a day for 6 months</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="126"/>
            <count group_id="B2" value="127"/>
            <count group_id="B3" value="253"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.8" spread="7.7"/>
                    <measurement group_id="B2" value="66.9" spread="8.2"/>
                    <measurement group_id="B3" value="66.4" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="126"/>
                    <measurement group_id="B2" value="127"/>
                    <measurement group_id="B3" value="253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Chinese</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="126"/>
                    <measurement group_id="B2" value="127"/>
                    <measurement group_id="B3" value="253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in the Prostate Volume at Month 6</title>
        <description>Percent change from baseline was calculated as the prostate volume at Month 6 minus the volume at baseline, divided by the prostate volume at baseline and multiplied by 100. Prostate volume was measured by transrectal ultrasound.</description>
        <time_frame>Baseline and Month 6</time_frame>
        <population>Intent-to-Treat (ITT) Population: all participants who were randomized to study treatment (after the 4-week placebo run-in) and received at least one dose of study treatment. Some participants were missing Month 6 measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride 0.5 mg</title>
            <description>Oral dutasteride 0.5 milligrams (mg) once a day for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching oral placebo once a day for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in the Prostate Volume at Month 6</title>
          <description>Percent change from baseline was calculated as the prostate volume at Month 6 minus the volume at baseline, divided by the prostate volume at baseline and multiplied by 100. Prostate volume was measured by transrectal ultrasound.</description>
          <population>Intent-to-Treat (ITT) Population: all participants who were randomized to study treatment (after the 4-week placebo run-in) and received at least one dose of study treatment. Some participants were missing Month 6 measurements.</population>
          <units>percent change in volume</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.00" spread="21.41"/>
                    <measurement group_id="O2" value="-2.77" spread="24.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-14.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-20.23</ci_lower_limit>
            <ci_upper_limit>-8.22</ci_upper_limit>
            <estimate_desc>Dutasteride arm minus placebo arm.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in the Prostate Volume at Month 3</title>
        <description>Percent change from baseline was calculated as the prostate volume at Month 3 minus the volume at baseline, divided by the prostate volume at baseline and multiplied by 100. Prostate volume was measured by transrectal ultrasound.</description>
        <time_frame>Baseline and Month 3</time_frame>
        <population>ITT Population. Some participants were missing Month 3 measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride 0.5 mg</title>
            <description>Oral dutasteride 0.5 milligrams (mg) once a day for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching oral placebo once a day for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in the Prostate Volume at Month 3</title>
          <description>Percent change from baseline was calculated as the prostate volume at Month 3 minus the volume at baseline, divided by the prostate volume at baseline and multiplied by 100. Prostate volume was measured by transrectal ultrasound.</description>
          <population>ITT Population. Some participants were missing Month 3 measurements.</population>
          <units>percent change in volume</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.02" spread="23.22"/>
                    <measurement group_id="O2" value="-1.02" spread="25.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Prostate Volume at Month 6</title>
        <description>Change from baseline was calculated as the prostate volume at Month 6 minus the volume at baseline. Prostate volume was measured by transrectal ultrasound.</description>
        <time_frame>Baseline and Month 6</time_frame>
        <population>ITT Population. Some participants were missing Month 6 measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride 0.5 mg</title>
            <description>Oral dutasteride 0.5 milligrams (mg) once a day for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching oral placebo once a day for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Prostate Volume at Month 6</title>
          <description>Change from baseline was calculated as the prostate volume at Month 6 minus the volume at baseline. Prostate volume was measured by transrectal ultrasound.</description>
          <population>ITT Population. Some participants were missing Month 6 measurements.</population>
          <units>cubic centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.16" spread="12.74"/>
                    <measurement group_id="O2" value="-1.20" spread="12.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Prostate Volume at Month 3</title>
        <description>Change from baseline was calculated as the prostate volume at Month 3 minus the volume at baseline. Prostate volume is measured by transrectal ultrasound.</description>
        <time_frame>Baseline and Month 3</time_frame>
        <population>ITT Population. Some participants were missing Month 3 measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride 0.5 mg</title>
            <description>Oral dutasteride 0.5 milligrams (mg) once a day for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching oral placebo once a day for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Prostate Volume at Month 3</title>
          <description>Change from baseline was calculated as the prostate volume at Month 3 minus the volume at baseline. Prostate volume is measured by transrectal ultrasound.</description>
          <population>ITT Population. Some participants were missing Month 3 measurements.</population>
          <units>cubic centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.11" spread="13.02"/>
                    <measurement group_id="O2" value="-1.06" spread="11.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in the Serum Dihydrotestosterone (DHT) at Month 6</title>
        <description>Percent change from baseline was calculated as serum DHT at month 6 minus the value at baseline ,divided by the baseline value and multiplied by 100.</description>
        <time_frame>Baseline and Month 6</time_frame>
        <population>ITT Population. Some participants were missing Month 6 measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride 0.5 mg</title>
            <description>Oral dutasteride 0.5 milligrams (mg) once a day for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching oral placebo once a day for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in the Serum Dihydrotestosterone (DHT) at Month 6</title>
          <description>Percent change from baseline was calculated as serum DHT at month 6 minus the value at baseline ,divided by the baseline value and multiplied by 100.</description>
          <population>ITT Population. Some participants were missing Month 6 measurements.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-52.53" spread="44.42"/>
                    <measurement group_id="O2" value="26.78" spread="149.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in the Serum DHT at Month 3</title>
        <description>Percent change from baseline was calculated as the DHT at Month 3 minus the value at baseline, divided by the baseline value and multiplied by 100.</description>
        <time_frame>Baseline and Month 3</time_frame>
        <population>ITT Population. Some participants were missing Month 3 measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride 0.5 mg</title>
            <description>Oral dutasteride 0.5 milligrams (mg) once a day for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching oral placebo once a day for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in the Serum DHT at Month 3</title>
          <description>Percent change from baseline was calculated as the DHT at Month 3 minus the value at baseline, divided by the baseline value and multiplied by 100.</description>
          <population>ITT Population. Some participants were missing Month 3 measurements.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-59.15" spread="37.90"/>
                    <measurement group_id="O2" value="28.33" spread="133.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Serum DHT at Month 6</title>
        <description>Change from baseline was calculated as the value of DHT at Month 6 minus the baseline value.</description>
        <time_frame>Baseline and Month 6</time_frame>
        <population>ITT Population. Some participants were missing Month 6 measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride 0.5 mg</title>
            <description>Oral dutasteride 0.5 milligrams (mg) once a day for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching oral placebo once a day for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Serum DHT at Month 6</title>
          <description>Change from baseline was calculated as the value of DHT at Month 6 minus the baseline value.</description>
          <population>ITT Population. Some participants were missing Month 6 measurements.</population>
          <units>picograms/milliliter (pg/ml)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-289.175" spread="270.610"/>
                    <measurement group_id="O2" value="-46.099" spread="399.806"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Serum DHT at Month 3</title>
        <description>Change from baseline was calculated as the value of DHT at Month 3 minus the baseline value.</description>
        <time_frame>Baseline and Month 3</time_frame>
        <population>ITT Population. Some participants were missing Month 3 measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride 0.5 mg</title>
            <description>Oral dutasteride 0.5 milligrams (mg) once a day for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching oral placebo once a day for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Serum DHT at Month 3</title>
          <description>Change from baseline was calculated as the value of DHT at Month 3 minus the baseline value.</description>
          <population>ITT Population. Some participants were missing Month 3 measurements.</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-319.605" spread="256.058"/>
                    <measurement group_id="O2" value="-34.400" spread="399.633"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in the American Urological Association Symptom Index (AUA-SI) Score at Month 6</title>
        <description>Percent change from baseline is calculated as the AUA-SI score at month 6 minus the baseline AUA-SI score, divided by the baseline score and multiplied by 100. AUA-SI is a self-administered questionnaire that assesses the severity of benign prostatic hyperplasia symptoms. Scores range from 0 to 35; mild, 0-7; moderate, 8-19; severe, 20-35.</description>
        <time_frame>Baseline and Month 6</time_frame>
        <population>ITT Population. Some participants were missing Month 6 measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride 0.5 mg</title>
            <description>Oral dutasteride 0.5 milligrams (mg) once a day for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching oral placebo once a day for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in the American Urological Association Symptom Index (AUA-SI) Score at Month 6</title>
          <description>Percent change from baseline is calculated as the AUA-SI score at month 6 minus the baseline AUA-SI score, divided by the baseline score and multiplied by 100. AUA-SI is a self-administered questionnaire that assesses the severity of benign prostatic hyperplasia symptoms. Scores range from 0 to 35; mild, 0-7; moderate, 8-19; severe, 20-35.</description>
          <population>ITT Population. Some participants were missing Month 6 measurements.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.48" spread="26.01"/>
                    <measurement group_id="O2" value="-20.79" spread="30.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in the AUA-SI Score at Month 3</title>
        <description>Percent change from baseline is calculated as the AUA-SI score at month 3 minus the baseline AUA-SI score, divided by the baseline score and multiplied by 100. AUA-SI is a self-administered questionnaire that assesses the severity of benign prostatic hyperplasia symptoms. Scores range from 0 to 35; mild, 0-7; moderate, 8-19; severe, 20-35.</description>
        <time_frame>Baseline and Month 3</time_frame>
        <population>ITT Population. Some participants were missing Month 3 measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride 0.5 mg</title>
            <description>Oral dutasteride 0.5 milligrams (mg) once a day for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching oral placebo once a day for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in the AUA-SI Score at Month 3</title>
          <description>Percent change from baseline is calculated as the AUA-SI score at month 3 minus the baseline AUA-SI score, divided by the baseline score and multiplied by 100. AUA-SI is a self-administered questionnaire that assesses the severity of benign prostatic hyperplasia symptoms. Scores range from 0 to 35; mild, 0-7; moderate, 8-19; severe, 20-35.</description>
          <population>ITT Population. Some participants were missing Month 3 measurements.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.64" spread="24.59"/>
                    <measurement group_id="O2" value="-11.91" spread="21.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the AUA-SI Score at Month 6</title>
        <description>Change from baseline was calculated as the AUS-SI score at month 6 minus the baseline score. AUA-SI is a self-administered questionnaire that assesses the severity of benign prostatic hyperplasia symptoms. Scores range from 0 to 35; mild, 0-7; moderate, 8-19; severe, 20-35.</description>
        <time_frame>Baseline and Month 6</time_frame>
        <population>ITT Population. Some participants were missing Month 6 measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride 0.5 mg</title>
            <description>Oral dutasteride 0.5 milligrams (mg) once a day for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching oral placebo once a day for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the AUA-SI Score at Month 6</title>
          <description>Change from baseline was calculated as the AUS-SI score at month 6 minus the baseline score. AUA-SI is a self-administered questionnaire that assesses the severity of benign prostatic hyperplasia symptoms. Scores range from 0 to 35; mild, 0-7; moderate, 8-19; severe, 20-35.</description>
          <population>ITT Population. Some participants were missing Month 6 measurements.</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.9" spread="4.8"/>
                    <measurement group_id="O2" value="-4.1" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the AUA-SI Score at Month 3</title>
        <description>Change from baseline was calculated as the AUA-SI score at month 3 minus the baseline score. AUA-SI is a self-administered questionnaire that assesses the severity of benign prostate hyperplasia symptoms. Scores range from 0 to 35; mild, 0-7; moderate, 8-19; severe, 20-35.</description>
        <time_frame>Baseline and Month 3</time_frame>
        <population>ITT Population. Some participants were missing Month 3 measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride 0.5 mg</title>
            <description>Oral dutasteride 0.5 milligrams (mg) once a day for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching oral placebo once a day for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the AUA-SI Score at Month 3</title>
          <description>Change from baseline was calculated as the AUA-SI score at month 3 minus the baseline score. AUA-SI is a self-administered questionnaire that assesses the severity of benign prostate hyperplasia symptoms. Scores range from 0 to 35; mild, 0-7; moderate, 8-19; severe, 20-35.</description>
          <population>ITT Population. Some participants were missing Month 3 measurements.</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" spread="3.9"/>
                    <measurement group_id="O2" value="-2.4" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Maximum Urinary Flow Rate (Qmax) at Month 6</title>
        <description>Percent change from baseline was calculated as Qmax at Month 6 minus Qmax at baseline, divided by baseline Qmax and multiplied by 100. Qmax is the peak urinary flow measured by a uroflow meter.</description>
        <time_frame>Baseline and Month 6</time_frame>
        <population>ITT Population. Some participants were missing Month 6 measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride 0.5 mg</title>
            <description>Oral dutasteride 0.5 milligrams (mg) once a day for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching oral placebo once a day for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Maximum Urinary Flow Rate (Qmax) at Month 6</title>
          <description>Percent change from baseline was calculated as Qmax at Month 6 minus Qmax at baseline, divided by baseline Qmax and multiplied by 100. Qmax is the peak urinary flow measured by a uroflow meter.</description>
          <population>ITT Population. Some participants were missing Month 6 measurements.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.14" spread="57.43"/>
                    <measurement group_id="O2" value="6.31" spread="47.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Qmax at Month 3</title>
        <description>Percent change from baseline was calculated as Qmax at Month 3 minus Qmax at baseline, divided by baseline Qmax and multiplied by 100. Qmax is the peak urinary flow measured by a uroflow meter.</description>
        <time_frame>Baseline and Month 3</time_frame>
        <population>ITT Population. Some participants were missing Month 3 measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride 0.5 mg</title>
            <description>Oral dutasteride 0.5 milligrams (mg) once a day for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching oral placebo once a day for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Qmax at Month 3</title>
          <description>Percent change from baseline was calculated as Qmax at Month 3 minus Qmax at baseline, divided by baseline Qmax and multiplied by 100. Qmax is the peak urinary flow measured by a uroflow meter.</description>
          <population>ITT Population. Some participants were missing Month 3 measurements.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.34" spread="42.86"/>
                    <measurement group_id="O2" value="5.85" spread="34.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Qmax at Month 6</title>
        <description>Change from baseline was calculated as Qmax at Month 6 minus Qmax at baseline. Qmax is the peak urinary flow measured by a uroflow meter.</description>
        <time_frame>Baseline and Month 6</time_frame>
        <population>ITT Population. Some participants were missing Month 6 measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride 0.5 mg</title>
            <description>Oral dutasteride 0.5 milligrams (mg) once a day for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching oral placebo once a day for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Qmax at Month 6</title>
          <description>Change from baseline was calculated as Qmax at Month 6 minus Qmax at baseline. Qmax is the peak urinary flow measured by a uroflow meter.</description>
          <population>ITT Population. Some participants were missing Month 6 measurements.</population>
          <units>milliliters/second (ml/s)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" spread="5.61"/>
                    <measurement group_id="O2" value="0.03" spread="5.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Qmax at Month 3</title>
        <description>Change from baseline was calculated as Qmax at Month 3 minus Qmax at baseline. Qmax is the peak urinary flow measured by a uroflow meter.</description>
        <time_frame>Baseline and Month 3</time_frame>
        <population>ITT Population. Some participants were missing Month 3 measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride 0.5 mg</title>
            <description>Oral dutasteride 0.5 milligrams (mg) once a day for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching oral placebo once a day for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Qmax at Month 3</title>
          <description>Change from baseline was calculated as Qmax at Month 3 minus Qmax at baseline. Qmax is the peak urinary flow measured by a uroflow meter.</description>
          <population>ITT Population. Some participants were missing Month 3 measurements.</population>
          <units>ml/s</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.93" spread="4.74"/>
                    <measurement group_id="O2" value="0.17" spread="4.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The Serious Adverse Events (SAEs) and Adverse Events (AEs) presented were collected in the 6-month Double-Blind Phase only.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Dutasteride 0.5 mg</title>
          <description>Oral dutasteride 0.5 milligrams (mg) once a day for 6 months</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Matching oral placebo once a day for 6 months</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Keratitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Stomach discomfort</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Prostatic specific antigen increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Red blood cells urine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Poor quality sleep</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Urethral pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Libido decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Pigmentation disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

